Veerhealth Care Limited filed a regulatory disclosure under SEBI Regulation 30 containing their audited financial results for the quarter and year ended March 31, 2026, along with a press release detailing financial performance and strategic updates.

Financial Results (Standalone FY26)

  • Total Income: ₹33.29 crore, representing 86.08% year-on-year growth
  • EBITDA: ₹3.27 crore, representing 82.68% year-on-year growth
  • EBITDA Margin: 9.82%, showing a year-on-year decline of 18 basis points
  • Net Profit: ₹0.54 crore, representing 38.16% year-on-year growth
  • Net Profit Margin: 1.62%, showing a year-on-year decline of 56 basis points

Exceptional Items Impacting Q4FY26 Profit

  • Forex Loss of ₹0.31 crore classified as exceptional items
  • Provision of ₹0.49 crore for Deferred Tax
  • The company stated it does not expect repeat of such expenses in FY27

Business Highlights and Strategic Updates

  • The India-EU Trade Deal 2026 is creating growth opportunities for Modern Ayurveda exports from India with reduced tariffs and improved regulatory access
  • European demand for natural healthcare is rising, benefiting Indian Ayurvedic products
  • Company is working on scaling manufacturing and export operations for medical device category products in the U.S. market
  • Ongoing discussions with a major Russian group for oral care exports, with expected entry into Russian market soon

Key Milestones Achieved in FY26

  • Export Orders: ₹119 crore from USA
  • Domestic Marketplace Orders: ₹0.28 crore
  • Domestic Pharmacy Chain Orders: ₹1.70 crore
  • Leading FMCG Company Orders: ₹10.08 crore
  • Completed onboarding of Ayuveer products on Myntra, expanding e-commerce presence across Amazon, Flipkart, Nykaa, Glowroad, Jiomart, and Myntra
  • Commenced production at new facility with in-house plastic molding for packaging and backward integration
  • Secured USFDA plant clearance, positioning the company in a distinctive category among small-cap companies

Company Business Description

Veerhealth Care Limited, through its brand Ayuveer, specializes in crafting ayurvedic medicines and oral care products with natural ingredients, with a focus on manufacturing Pure Vegetarian toothpaste.

Forward Guidance

  • FY27 Expectations: Total revenues of ₹70-75 crore with PAT of 7-10%
  • 24-Month Target: Reach revenues of ₹100 crore with PAT of 10%

Management Commentary

Mr. Bhavin Shah, Managing Director, commented: "I am delighted with the strides we have made in FY26 by reporting Highest ever Total Revenues of ₹33.29 crore, driven by our consistent focus on expanding our international footprint and strengthening our domestic presence. The growth in our Export Sales and the addition of new product categories have significantly bolstered our position in the global and local markets. As per existing Order Book in hand we expect to maintain the high growth rates which we have delivered in FY26. These achievements are a testament to our strategy and pave the way for sustained growth and value creation in the coming quarters."

Disclaimer Included

The document contains forward-looking statements subject to risks and uncertainties including government actions, local/political/economic developments, technological risks, and other factors. The company will not be responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements.